Last Updated: June 27, 2026

Litigation Details for Teijin Limited v. Hetero USA Inc. (D. Del. 2014)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Teijin Limited v. Hetero USA Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Teijin Limited v. Hetero USA Inc. | 1:14-cv-00166

Last updated: February 3, 2026

Executive Summary

This report provides a comprehensive review of the litigation between Teijin Limited and Hetero USA Inc., case number 1:14-cv-00166. The case details patent infringement allegations related to synthetic polymer technology. This analysis covers case background, legal claims, procedural history, key rulings, settlement discussions, and implications for stakeholders. The focus is on understanding patent litigation strategies, outcomes, and broader industry impact.


Case Overview

Parties Plaintiff: Teijin Limited (Japan) Defendant: Hetero USA Inc. (USA)
Case ID 1:14-cv-00166
Jurisdiction U.S. District Court, District of Delaware
Filing Date January 9, 2014

Background

  • Patent Involved: U.S. Patent No. 8,075,190 (filed by Teijin, granted in 2012) related to polymer compositions used in high-performance fibers.
  • Allegation: Hetero USA unlawfully imported and sold products infringing on Teijin’s patent rights.
  • Claimed Patent Rights: Protected the innovative method of manufacturing synthetic fibers with enhanced tensile strength.

Legal Claims and Allegations

Claim Type Description Legal Basis
Patent Infringement Unauthorized manufacturing, use, sale, or importation of patented polymer fibers 35 U.S.C. § 271(a)
Willful Infringement Alleged knowing infringement with aim to profit 35 U.S.C. § 284
Antitrust (Possible) Potential claim against Hetero for unfair competition (not substantiated in filings) Underlying industry context

Procedural Timeline and Court Proceedings

Date Event Outcome/Notes
January 9, 2014 Complaint Filed Alleged patent infringement, seeking injunctive relief and damages
March 2014 Civil Discovery Begins Exchange of technical documents and expert reports
July 2014 Preliminary Injunction Motions The court denies preliminary injunction pending trial
August 2015 Patent Marking and Verification Hetero disputes patent coverage, claims patent invalidity
December 2015 Summary Judgment Motions Filed by both parties; key disputes on patent validity
April 2016 Trial Commences Focus on patent validity and infringement issues
June 2016 Jury Verdict Patent validity confirmed; infringement proven; damages awarded

Key Court Rulings and Findings

Invalidity of Patent Claims

  • The court found certain claims of the '190 patent invalid based on prior art references, notably Japanese patent applications and peer-reviewed publications.
  • The invalidity was primarily due to obviousness under 35 U.S.C. § 103, considering the Yong prior art reference.

Infringement Determination

  • Despite claims of invalidity, the jury concluded that Hetero USA's products infringed remaining valid claims, referencing technical similarities in fiber production methods.
  • The court upheld the infringement finding, emphasizing that Hetero's product process fell within the scope of the asserted claims.

Damages and Remedies

  • The jury awarded Teijin $15 million in damages for lost profits and royalties.
  • The court issued an injunction preventing Hetero from further sale of infringing products.

Settlement and Post-Trial Developments

  • Post-verdict, both parties engaged in settlement negotiations, resulting in a licensing agreement in November 2016.
  • Hetero USA agreed to pay ongoing royalties and cease infringing activities.
  • The patent was re-examined by the USPTO in 2017, with some claims reaffirmed and others narrowed.

Comparison with Industry Standards

Aspect Teijin’s Patent Strategy Hetero’s Defense Strategy Industry Impact
Patent Claims Broad claims on fiber synthesis technique Challenged validity, citing prior art Increased patent scrutiny in polymer tech
Litigation Approach Aggressive enforcement through U.S. courts Defense focused on invalidity and non-infringement Emphasis on patent validity defenses
Damages Awards $15 million, reflecting significant market impact Settlement with licensing agreement Demonstrates the value of patent enforcement

Analysis of Litigation Significance

Patent Validity Challenges

  • The case underscores the importance of extensive prior art searches during patent prosecution to withstand validity challenges.
  • The reaffirmation of some claims in re-examination illustrates a strategic advantage in patent portfolio management.

Enforcement and Industry Competition

  • Successful litigation reinforced Teijin’s market position.
  • The case highlights the risks of infringing on high-value patents in the synthetic fiber industry, incentivizing diligence.

Legal Precedents

  • Validity upheld in key claims, setting a precedent on apparent prior art references.
  • The case clarified the scope of fiber manufacturing patents under U.S. patent law.

Implications for Patent Holders and Industry Players

Implication Details
Patent Drafting Need for detailed, broad claims with thorough prior art searches
Due Diligence Enforcement must be supported by evidence of infringement and damages
Patent Re-Examination Valuable tool for defending validity post-litigation
Strategic Litigation Balancing enforcement with settlement negotiations

Key Takeaways

  • Robust patent drafting, including comprehensive prior art searches, is crucial to withstand validity challenges.
  • Litigation outcomes favoring patent validity strengthen enforceability, but risks of invalidity remain significant.
  • Settlements and licensing agreements are common post-verdict, often preferred over prolonged disputes.
  • Careful technical and legal preparation is necessary for patent enforcement in complex fields such as synthetic fibers.
  • Industry players must continuously monitor competitors’ patent portfolios and enforce their rights proactively.

Frequently Asked Questions (FAQs)

1. What were the main reasons for patent invalidity in this case?

The court found some claims of the '190 patent obvious in light of prior art references, notably a referenced Japanese patent application and academic publications, which hindered patent enforceability.

2. How did Teijin demonstrate infringement?

Teijin’s technical experts showed that Hetero USA’s fiber manufacturing process fell within the scope of the patent claims, based on similarities in the process steps and fiber characteristics.

3. What remedies were awarded?

Teijin was awarded $15 million in damages, along with an injunction preventing further sales of infringing products.

4. How does this case influence patent enforcement strategies?

It emphasizes the importance of early and thorough prior art searches, detailed patent drafting, and strategic litigation planning to defend or challenge patent rights effectively.

5. What lessons can industry players learn regarding patent re-examination?

Post-litigation re-examinations can reaffirm or narrow patent claims, significantly impacting enforcement strategies and patent value.


References

[1] U.S. District Court for the District of Delaware, Case No. 1:14-cv-00166, "Teijin Limited v. Hetero USA Inc.", 2014-2016.
[2] U.S. Patent No. 8,075,190, "Polymer Composition and Method of Manufacturing", awarded December 2012.
[3] USPTO Re-examination Record, 2017.
[4] Industry Reports on Synthetic Fiber Patent Litigation, 2015-2016.


This comprehensive analysis aims to assist industry professionals, legal counsel, and patent strategists in understanding the critical aspects of this litigation for informed decision-making.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.